Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valaciclovir + aciclovir
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valaciclovir and aciclovir are both antiviral medications used to treat herpes virus infections. Valaciclovir is a prodrug of aciclovir, meaning it's converted to aciclovir in the body after administration. Both medications inhibit viral DNA synthesis after phosphorylation to the active triphosphate form, and are effective against various herpes viruses including HSV-1, HSV-2, VZV, CMV, and EBV.
- Brand names
- Zovirax + ValtrexSitavig + ValtrexXerese + Valtrex
- Other names
- valacyclovir + acyclovir
02
Targets
BALF5 (Epstein-Barr virus DNA polymerase)HSV DNA pol (Herpes simplex virus DNA polymerase)POLA1 (DNA polymerase alpha)POLB (DNA polymerase beta)Herpesvirus DNA polymerase
Beyond the preview
Go deeper on valaciclovir + aciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valaciclovir + aciclovir.